{'fraction_non_alphanumeric': 0.054194506310319225, 'fraction_numerical': 0.04825538233110616, 'mean_word_length': 4.760683760683761, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CLINICAL AND LABORATORY CHARACTERISTICS OF MILD/MODERATE COVID-19 IN PREGNANT WOMEN, BASED ON THE DURATION OF GESTATION

The study deals with the clinical and laboratory manifestations of mild and moderate forms of COVID-19 depending on the gestational period in 69 pregnant women aged 18 to 41 (28.5 +/- 6.9), hospitalized with a "COVID-19" diagnosis. The patients under study exhibited no significant differences in clinical symptoms and main laboratory data, including coagulogram (p >0.05) throughout three trimesters of pregnancy. The severity of COVID-19 in pregnant women most likely depends on the presence of concomitant extragenital pathology and burdened gynecological history (pathology of previous pregnancies and childbirth) rather than on gestational period (pathology of previous pregnancies and childbirth), since more often these pathologies occurred in pregnant women with moderate COVID-19. The research showed that women in all three trimesters of pregnancy showed a significant increase (p <0.05) in C-reactive protein, a specific marker of inflammation, the findings, obtained in the 2nd and 3rd trimesters of pregnancy (26.7 +/- 21.97 and 32.7 +/- 26.5 mg/l) insignificantly (p1-3 = 0.056, p2-3 = 0.231) exceeded those, observed in the 1st trimester (14.8 +/- 26.9). Copyright (C) 2013 - All Rights Reserved - Pharmacophore